RE: Take over price.16 Oct 2024 09:15
‘Judging by its share price’ is probably the worst way to value stock at this particular moment. We have had two large dividends in the last 12 months and now a buy back that actually rewards shareholders while rating value in the company. I admit 6 percent of a 22 percent premium is not huge as a one off, but this is hardly a one off. It’s the third return of cash to shareholders in less than a year , about 50 million in total! Straight buybacks rarely increase value to shareholders. This way we get some more cash and the company hold half the shares in treasury and cancel the rest. On top of this growth looks set to continue with a potential market of 340 million people of which only about 17 million currently have access to their diagnostic test. This is being up graded right now with new roll out. Thermo Fisher and a couple of others acting as agents in the burgeoning USA market. They have very little capex spend in doing this and developing home test kit, which is taking a little longer than I was expecting. They have no plans to move in a new direction thus not exposing new risk to capital. A very nice growing cash generating business with the hidden asset of 600 million tax credit from their disastrous Cicassia days. I can see the market is going to completely over play this small payout. The payout is more or less covered by the retention and cancelation of shares while the value is cleverly retained within the company and attractive to a suitor at the right price